Drug discovery

Kantify has developed ZeptoNet - a novel AI technology that can perform in silico high-throughput screening on small molecules. ZeptoNet can help accelerate the early drug discovery process, reduce clinical trials failure rate and help with drug repurposing.

Focus: Drug discovery platform 

Team: Nik Subramanian and Segolene Martin

Website: https://www.kantify.com/

Be part of SBC Catalyser Programme!

Spaces are limited to a maximum of 10 companies per cohort. Contact Marco to know more or to apply.

Contact Marco

We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.